Core Insights - The report by KPMG highlights the dynamic and growth-oriented nature of China's biotechnology sector, emphasizing the interplay of policy, technology, capital, and international collaboration in driving industry transformation [1][2] - The integration of artificial intelligence in the healthcare sector is creating unprecedented opportunities, enhancing research efficiency, product innovation, and supply chain optimization [1] - The report indicates that China's innovation-driven pharmaceutical sector is entering a golden development period, with a shift from cost competition to value creation in the CDMO space [1] Industry Trends - China's biotechnology industry is becoming increasingly significant in the global innovation landscape, focusing on emerging areas such as cell therapy, gene therapy, in vitro diagnostics, and AI-driven pharmaceuticals [2] - The globalization of Chinese biopharmaceuticals has transitioned from an optional strategy to a necessary one, with a notable increase in license-out transactions since 2020 [2] - The deep integration of scientific innovation and business models is identified as a key factor for success in the current biotechnology landscape [2]
解码中国生物科技发展 毕马威第三届生物科创领航50企业报告正式发布
Zheng Quan Ri Bao Wang·2025-10-15 10:18